Epitope-Specific Tolerance Modes Differentially Specify Susceptibility to Proteolipid Protein-Induced Experimental...

Area of Science:

• Immunology
• Neuroscience
• Autoimmunity

Background:

• Experimental autoimmune encephalomyelitis (EAE) is induced by myelin components, with susceptibility varying by mouse strain and antigen.
• Proteolipid protein (PLP)-specific tolerance in resistant BL/6 mice is not fully understood.
• Understanding PLP tolerance mechanisms is crucial for developing antigen-specific therapies for autoimmune diseases.

Purpose of the Study:

• To investigate the mechanisms of central and peripheral tolerance to proteolipid protein (PLP) in mice.
• To determine how different PLP epitopes influence experimental autoimmune encephalomyelitis (EAE) susceptibility.
• To elucidate the role of thymic epithelial cells (TECs) and dendritic cells in establishing immune tolerance.

Main Methods:

• Identification of PLP epitopes in PLP-deficient and sufficient mice.
• Induction of EAE using specific PLP epitopes in wild-type and T cell receptor (TCR) transgenic mice.
• Analysis of central tolerance mechanisms (clonal deletion, T regulatory cell induction) in the thymus.
• Assessment of peripheral tolerance mechanisms (deletion, anergy) mediated by dendritic cells.
• TEC-specific ablation of PLP to study its role in central and peripheral tolerance.

Main Results:

• Only one of three identified PLP epitopes was encephalitogenic, correlating with weak MHCII binding and leaky tolerance.
• Central tolerance mechanisms, including autoimmune regulator (AIRE)-dependent TEC presentation, controlled tolerance to specific epitopes.
• Peripheral tolerance mechanisms compensated for lack of central tolerance, but thymic PLP expression was essential for dominant tolerance.

Conclusions:

• Immune tolerance to PLP is multi-layered, epitope-specific, and critical for preventing EAE.
• Both central tolerance in the thymus and peripheral tolerance mediated by dendritic cells contribute to self-antigen recognition.
• Understanding epitope-specific tolerance is key for developing targeted immunotherapies for autoimmune CNS diseases.